Linked Life Data

16034896

Source:http://linkedlifedata.com/resource/pubmed/id/16034896

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2005-7-21
pubmed:abstractText
Treatment with recombinant human erythropoietin (rHu EPO) in dialysis patients has been shown to be highly effective in terms of correcting anaemia and improving quality of life. There is debate concerning the benefits of rHu EPO use in pre-dialysis patients which may accelerate the deterioration of renal function. However the opposing view is that if rHu EPO is as effective in pre-dialysis patient's, improving the patients sense of well-being may result in the onset of dialysis being delayed.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1469-493X
pubmed:author
pubmed:issnType
Electronic
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
CD003266
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.
pubmed:affiliation
Cochrane Incontinence Review Group, University of Aberdeen, Health Services Research Unit, Polwarth Building, Foresterhill, Aberdeen, UK, AB25 2ZD. j.cody@abdn.ac.uk
pubmed:publicationType
Journal Article, Review, Meta-Analysis